Is Higher Adherence Required for Women Using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis?

Clin Infect Dis. 2024 Mar 20;78(3):801-802. doi: 10.1093/cid/ciad485.

Authors

Xin Niu¹, Paul K Drain^{1

2

3}

Affiliations

¹ Department of Epidemiology, University of Washington, Seattle, Washington, USA.
² Department of Global Health, University of Washington, Seattle, Washington, USA.
³ Department of Medicine, University of Washington, Seattle, Washington, USA.

PMID: 37586099
DOI: 10.1093/cid/ciad485

No abstract available

Publication types

Letter

MeSH terms

Emtricitabine / therapeutic use
Female
HIV*
Humans
Tenofovir / therapeutic use

Substances

Tenofovir
Emtricitabine